Results 91 to 100 of about 48,006 (264)

Adherence to Clotting Factor Prophylaxis in Adolescent and Adult Males With Haemophilia

Haemophilia, EarlyView.
ABSTRACT Introduction Clotting factor prophylaxis remains the most prescribed standard‐of‐care treatment for people with haemophilia (PwH). Prophylaxis prevents bleeds, joint damage, and improves quality of life (QoL). Its success depends on treatment adherence, consisting of socioeconomic, behavioural, and disease‐ or therapy‐related factors.
Nathália Martins Beserra, Ricardo Mesquita Camelo, Alice Oliver Rosa Sacramento, Eliziane Souza Nascimento, Rosângela Pinheiro Gonçalves Machado, Clarissa Maria Gonçalves Machado, Suzzy Maria Carvalho Dantas, Samuel Gonçalves Machado da Rocha, Luany Elvira Mesquita Carvalho, Romélia Pinheiro Gonçalves Lemes   +9 more
wiley   +1 more source

Factors Influencing Sport‐Induced Bleeding in Patients With Haemophilia Without Inhibitors: A Single Centre Retrospective Study of People Born in the 2000s

Haemophilia, EarlyView.
ABSTRACT Introduction Recent advances in prophylaxis with clotting factor concentrates have enabled people with haemophilia (PwH) to participate in high‐intensity exercises; however, this does not preclude them from sports‐induced bleeding (SIB). Aim To investigate factors influencing the recent occurrence of SIB among PwH.
Rie Shirayama, Takuma Ito, Tetsuji Sato, Takayuki Hoshina   +3 more
wiley   +1 more source

A Case of Heel Reconstruction with a Reverse Sural Artery Flap in a Hemophilia B Patient

Archives of Plastic Surgery, 2012
Hemophilia B is a rare blood coagulation disorder. Complications such as bleeding and hematoma can cause necrosis of flaps, wound disruption, and the disturbance of wound healing.
Byung Kwon Lee, Jeong Su Shim
doaj   +1 more source

Correlations between patient-reported outcomes and self-reported characteristics in adults with hemophilia B and caregivers of children with hemophilia B: analysis of the B-HERO-S study

Patient Related Outcome Measures, 2019
Tyler W Buckner,1 Robert Sidonio Jr,2 Michelle Witkop,3 Christine Guelcher,4 Susan Cutter,5 Neeraj N Iyer,6 David L Cooper6 1Hemophilia and Thrombosis Center, University of Colorado School of Medicine, Aurora, CO, USA; 2Department of Pediatrics, Aflac ...
Buckner TW, Sidonio Jr R, Witkop M, Guelcher C, Cutter S, Iyer NN, Cooper DL   +6 more
doaj  

Emergencies in Hemophiliacs

Journal of Education and Teaching in Emergency Medicine, 2016
Audience: This modified team-based learning (mTBL) session is appropriate for medical students or emergency medicine residents. Introduction: Hemophilia is an x-linked recessive disorder leading to a decrease in functional clotting factors; there ...
Alisa Wray
doaj   +1 more source

Delivery of human apolipoprotein (apo) E to liver by an [E1(-), E3(-), polymerase(-), pTP(-)] adenovirus vector containing a liver-specific promoter inhibits atherogenesis in immunocompetent apoE-deficient mice [PDF]

, 2006
Recombinant adenovirus (rAd)-mediated apoE gene transfer to the liver of apoE(-/-) mice is anti-atherogenic. However, first generation rAd vectors were associated with immune clearance of transduced hepatocytes, while an improved [E1(-), E3(-) polymerase(
Amalfitano, A, Dickson, G, Graham, IR, Harris, JD, Owen, JS   +4 more
core  

High-levelexpression of functional recombinant human coagulation factor VII in insect cells [PDF]

: Recombinant coagulation factor VII (FVII) is used as a potential therapeutic intervention in hemophilia patients who produce antibodies against the coagulation factors.
AD Shapiro, Ali Jahanian Najafabadi, Amaneh Mohammadi Roushandeh, B Brenner, B Furie, BG Maick, CR Hay, DA Roth, DE Lynn, DR O’Reilly, G Bray, G Kemball-Cook, HJ Cha, I Nillson, KR Kim, Mahdi Edalati Fathabad, Mahdi Rouhbakhsh, Mahshid Mohammadipour, Mehryar Habibi Roudkenar, MK Miller, Mohamad Ali Shokrgozar, Mohamad Salimi, N Wajih, Nasser Masroori, R Halabian, R Toso, Raheleh Halabian, SM Ruiz, SM Wu, T Li, UK Laemmli   +30 more
core   +1 more source

Thrombin Generation in Pediatric Haemophilia A Patients on Extended Half‐Life FVIII versus Non‐FVIII Therapies

Haemophilia, EarlyView.
ABSTRACT Introduction The therapeutic landscape for patients with haemophilia A (PwHA) is rapidly evolving with the introduction of extended half‐life FVIII (EHL‐FVIII) and non‐FVIII therapies that mimic FVIII, such as emicizumab (EMI). Monitoring non‐factor therapies in the laboratory poses challenges; however, the thrombin generation assay (TGA) can ...
Jessica Garcia, Sean G. Yates, Ravi Sarode, Guy Young, Ayesha Zia   +4 more
wiley   +1 more source

Evidence-based dental management strategies for individuals with congenital hemophilia: a systematic review

BMC Oral Health
Background People with hemophilia commonly present with a range of bleeding symptoms, from minor oral cavity bleeds to life-threatening events such as intracranial hemorrhage.
Mathangi Kumar, Sulochana Badagabettu, Keerthilatha M Pai, Linu Sara George   +3 more
doaj   +1 more source

Delphi Consensus Recommendations for the Definition of a Severe Bleeding Phenotype and Initiation of Prophylaxis in Patients With Non‐Severe Haemophilia

Haemophilia, EarlyView.
ABSTRACT Introduction Current guidelines recommend prophylaxis for patients with non‐severe haemophilia with severe bleeding phenotype (SBPT) but there is no consensus how to define a SBPT and when to recommend prophylaxis in patients with non‐severe haemophilia. Method A Delphi consensus procedure among the members of the Standing Committee Hemophilia
Christian Pfrepper, Cihan Ay, Ralf Knöfler, Christoph Königs, Manuela Krause, Wolfgang Miesbach, Johannes Oldenburg, Michael Sigl‐Kraetzig, Rosa Sonja Alesci, Martin Olivieri, for the Standing Committee Hemophilia of the GTH   +10 more
wiley   +1 more source